MONTREAL, QUEBEC -- (MARKET WIRE) -- October 25, 2006 -- Theratechnologies (TSX: TH) announced today that it has completed the efficacy phase (26 weeks of treatment) of its first Phase 3 clinical trial testing TH9507 in HIV-associated lipodystrophy. The Company is now proceeding to assemble and refine the data with a view to locking the database in December. Once these steps have been completed, the results will be analyzed and made public.
